Allied Academic Publication is an amalgamation of several esteemed academic and scientific associations known for promoting scientific temperament. Established in the year 1997, Andrew John Publishing Group is a specialized Medical publisher that operates in collaboration with the association and societies. This publishing house has been built on the base of esteemed academic and research institutions including The College of Audiologists and Speech Language Pathologists of Ontario(CASLPO), The Association for Public Safety Communications Officials of Canada (APCO), The Canadian Vascular Access Association (CVAA), The Canadian Society of Internal Medicine (CSIM), The Canadian Hard of Hearing Association (CHHA), Sonography Canada, Canadian Association of Pathologists (CAP-ACP) and The Canadian Association of Neurophysiologic Monitoring (CANM).
NeuropharmacologyCongress 2017 is an international platform for sharing knowledge and representing work in the field of neuropharmacology, neurochemistry, pharmacology, psychopharmacology, neurotoxicology under the theme “Investigating Combats in Neuropharmacology”. The conference aims at promoting interaction among the researchers, students, industrial professionals, neurologists, neurosurgeons, pharmacists from all around the globe. It is a campaign to create awareness about the recent advancements, researches, breakthroughs, technology developed in the area of Neuropharmacology-Neurochemistry. Neuropharmacology Congress 2017 will serve as a motivation for the young scientists and an appreciation for the senior members of the Neuropharma Family. We invite you to join us with your prestigious studies & together we will make this world a better place to live.
Importance: Neuropharmacology deals with the area of Neuroscience, which relates drugs with the nervous system and studies the interaction between them. It includes the mechanisms involved, various types of drugs, effect of the drugs on behaviour, variations at the molecular level. Neurochemicals and molecules such as neurotransmitters, neuropeptides, psychopharmaceuticals influence the functioning of neurons, which is studied under Neurochemistry. Neuropharmacology and Neurochemistry, together opens door towards the understanding of the interactions in the nervous system at molecular level, which in turn assists in developing innovative diagnostic techniques, therapies for the neurological & psychiatric disorders.
Welcome to the Official Attendee Housing Site for the "Global Neuropharmacology and Neurochemistry Congress", which will be held in Las Vegas, USA.
Track 1: Neurochemistry & Neurotransmission
Neurochemistry deals with the processes happening in nervous system and nerve tissues. One of these processes is Neurotransmission, wherein, the interaction at the synapse occurs with the help of neurotransmitters such as Dopamine, Acetylcholine, Norepinephrine, Glutamate, Serotonin, Gamma-aminobutyric acid (GABA), Endogenous opioids etc. Activity of ion channels assists neurotransmitter receptors to receive the signals. This mechanism is altered by the many drugs, as a treatment process of neurological disorders.
The global sales of drugs to treat progressive dementia with other neurological abnormalities expected to reach $537.2 million in 2012 and $913.7 million by 2017, at a CAGR of 11.2% over the five-year forecast period.
Track 2: Neuroimmunology
Neuroimmunology plays an important role in the development of pharmaceutical therapies for various neurological disorders. It constitutes of two complex systems of the body i.e. nervous system and immune system, malfunctioning of either or both can lead to various stress situations. Endocrine and nervous system combines to carry out various physiological activities and their interaction with each other is studied under Neuroendocrinology.
The global G protein, coupled receptors (GPCR) targeting drug market sharply fell in the last three years due to a series of patent expirations of blockbuster products. The market receded from nearly $111 billion to almost $100 billion with a -3.4% compound annual growth rate (CAGR) between 2010 and 2013. With the introduction of novel pharmacecuticals and newly appearing classes of drugs, Research expects this market to reach $114 billion by 2018, a CAGR of 2.7% from 2013 to 2018.
Track 3: Neuropathology
Neuropathology is a substantial element of the fundamental study of disease and a foremost field in current medication and diagnosis. The diagnostics is done on the basis of brain/spinal cord tissue, which is received after biopsy. It has been an important tool in the diagnostics of prion disease and mitochondrial disease.
The global market for spinal and neurostimulation intervention products is expected to reach $15.8 billion by 2021 from $12.6 billion in 2016, rising at a compound annual growth rate (CAGR) of 4.5% from 2016 through 2021.
Track 4: Neuroethics
With the advancement in the field of neuroscience, there are many social, ethical and legal issues which have come into picture. From clinical trial of drugs to the application of drugs, from reading of brain to the memory loss, in various psychiatric disorders, ethics are associated in every step. Neuroethics acts as a bridge between science and law.
Track 5: Neuroscience
Neuroscience is concerned with all the fields such as structural, molecular, mathematical, computational; developmental which are required to understand brain and its functions. It is an interdisciplinary field which counts on all the aspects of science, required to study nervous system, spinal cord, networking and signalling process.
The global market for neuromarketing technology reached $21.0 million in 2015. The market is expected to reach $22.0 million by 2021 from $50.3 million in 2016, increasing at a compound annual growth rate (CAGR) of 18.0% from 2016 to 2021.
Neuro-Ophthalmology is the amalgamation of visual system and nervous system. Study suggests that we use almost half of the brain for the vision related activities. Accurate measurement of motor reactions is vital for understanding the oculomotor system. Eye movements provide a window on fundamental brain function, not only for topographic diagnosis of dysfunctions but also for the knowledge of normal brain function.
Track 7: Neurotoxicity of Drugs
Neurotoxicity is the result of exposure of the nervous system to the artificial or natural toxic agents. These agents can be heavy metals, drugs, radiations, pesticides or solvents. They work by disrupting the signaling process in between the neurons leading to the bulk of problems. Neurotoxicity has been reported as a major cause of Alzheimer’s disease, which is a neurodegenerative disorder.
The global market for AD therapeutics and diagnostics by region should reach over $6.2 billion by 2020 from $4.4 billion in 2015, at a compound annual growth rate (CAGR) of 7.1% from 2015 to 2020.
Track 8: Paediatric Neuropharmacology
Pediatric neuropharmacology deals with the neurological disorders in children such as seizures, delayed speech, weakness, or headaches. ADHD is also a neurodevelopmental disorder, which occurs at the age of six to twelve. The symptoms are excessive activity, inattention, disruptive or impulsive behaviour.
Overall, about 40% to 50% of the patients treated in a typical pediatric neurology practice have epilepsy, while 20% have learning difficulties or developmental problems and 20% are suffering from headaches.
Track 9: Addiction & Psychopharmacology
Addiction is a condition wherein the person indulges himself in rewarding stimuli, regardless of adverse consequences. Psychopharmacology is the study of effect of drugs which lead to change in behaviour. It implicates the modification at molecular level that can be observed in the terms of behavioural changes.
The global market for drugs used in mental disorders was $70.1 billion in 2012 and $68.9 billion in 2013. This market is expected to rise at a compound annual growth rate (CAGR) of 2.3% from 2013 to 2018 and reach $77.1 billion by 2018.
Track 10: Neuronal Stem Cells
Neural repair works on the principle of replacing damaged/infected cells with the healthy cells. Neural stem cells play a vital role in regenerative medication as these are self-renewing and multipotent. These stem cells have proved to be a boon in Neurological conditions, such as Huntingdons disease, Parkinson's disease and Motor Neuron Disease.
The global stem cell market reached over $5.9 billion in 2015 and will grow from about $6.7 billion in 2016 to nearly $12.3 billion in 2021, registering a compound annual growth rate (CAGR) of 13.1% from 2016 through 2021.
Track 11: Physiology and Signaling
The brain contains roughly 100 billion neurons, with each neuron forming connections with up to thousands of other neurons. These connections are called synapse. This mechanism comprise of various complex pathways, ion channels, receptors, proteins and junctions. Cell signaling and cell physiology have allowed studies of molecular processes in the context of the integrated behavior of cells and their organelles, and of tissues and organs, and whole organism.
The global CNS biomarker market was estimated at $1.7 billion in 2011 and nearly $2 billion in 2012. The market is projected to reach $5.1 billion by the end of the forecast period of 2012 to 2017, representing a compound annual growth rate (CAGR) of 20.7%.
Track 12: Psychiatric Disorders
Psychiatric Disorders are patterns of behavioral or psychological symptoms that affect various areas of life. Autism is a severe developmental disorder that damages the ability to communicate and interact. Schizophrenia is a brain disorder in which people understand reality abnormally. Dementia is an assembly of thinking and social symptoms that obstructs with daily functioning.
The global autism spectrum disorders (ASD) market was valued at $346.2 million in 2013 and $360.9 million in 2014. This market is expected to grow to $412.7 million by 2019, a compound annual growth rate (CAGR) of 2.7%.
Track 13: Neurological disorders
Neurological disorders are sicknesses of the brain, spine and the nerves that connect them. These disorders include epilepsy, Alzheimer disease and other dementias, cerebrovascular diseases including stroke, Parkinson's disease, migraine and other headache disorders, brain tumours, multiple sclerosis, neuroinfections, traumatic disorders of the nervous system due to head trauma, and neurological disorders as a result of malnutrition.
The global stroke management market was valued at $19.2 billion in 2013 and nearly $20.2 billion in 2014. This market is expected to reach nearly $28.3 billion by 2019, with a compound annual growth rate (CAGR) of 7% from 2014 to 2019.
Summary: Neuropharmacology Congress 2017 is an international platform for sharing knowledge and representing work in the field of neuropharmacology, neurochemistry, pharmacology, psychopharmacology, neurotoxicology under the theme “Investigating Combats in Neuropharmacology”. The conference aims at promoting interaction among the researchers, students, industrial professionals, neurologists, neurosurgeons, pharmacists from all around the globe. It is a campaign to create awareness about the recent advancements, researches, breakthroughs, technology developed in the area of Neuropharmacology-Neurochemistry. Neuropharmacology Congress 2017 will serve as a motivation for the young scientists and an appreciation for the senior members of the Neuropharma Family. We invite you to join us with your prestigious studies & together we will make this world a better place to live.
Scope: Neuropharmacology deals with the area of Neuroscience, which relates drugs with the nervous system and studies the interaction between them. It includes the mechanisms involved, various types of drugs, effect of the drugs on behaviour, variations at the molecular level. Neurochemicals and molecules such as neurotransmitters, neuropeptides, psychopharmaceuticals influence the functioning of neurons, which is studied under Neurochemistry. Neuropharmacology and Neurochemistry, together opens door towards the understanding of the interactions in the nervous system at molecular level, which in turn assists in developing innovative diagnostic techniques, therapies for the neurological & psychiatric disorders.
Why Las Vegas, USA?
The global market for drugs used in mental disorders was $70.1 billion in 2012 and $68.9 billion in 2013. This market is expected to enlarge at a compound annual growth rate (CAGR) of 2.3% from 2013 to 2018 and reach $77.1 billion by 2018. North America dominated the market in 2014, with revenue estimated at over USD 2,400 million. Presence of sophisticated healthcare infrastructure, favorable government initiatives pertaining to pharmaceutical R&D, cancer research, neurological R&D investment, and the presence of a considerably large CNS disorder patient base are some drivers of this market. Las Vegas itself is a home of many pharmaceutical companies such as mtibio, Invisicare , Sterling-Hoffman Life Sciences, ProHealth, AstraZeneca, Regeneron Pharmaceuticals, and universities like University of Nevada. Las Vegas is also a famous tourist destination. The major attraction includes The Mirage, Las Vegas Strip, Bellagio, Caesars Palace, Red Rock Canyon, and Fremont Street.
Global neurology devices market is expected to reach USD 10.8 billion by 2022. This expected growth in demand can be ascribed to growing need for development of different neurostimulation techniques with efficient and accurate algorithms for treatment of several CNS associated disorders.
Rise in incidence of cerebral stroke and other severe disorders such as Alzheimer’s disease, epilepsy, and Parkinson is is expected to fuel demand of neurology devices thereby driving industry growth. According to National Institute of Neurological Disorders and Stroke (NINDS), approximately 50 million Americans are affected due to these disorders leading to high economic & disease costs burden for medical expenses coupled with loss of productivity. The industry is expected to witness a considerable increase in demand for CNS related therapeutic procedures over the forecast period.
The global neurology devices market size was valued at USD 6.2 billion in 2014. Growing advancement in the field of imaging technologies and consequent development of neurosurgical endoscopy devices are likely to drive growth over the forecast period. Further increase in the number of neuroinformatics related projects for provision of efficient algorithms are also attributive factors expected to boost demand over the forecast period.
Epilepsy is a chronic neurological disorder characterized by unpredictable seizures. Epilepsy is the fourth most common neurological disorder that affects peoples of all age group. Seizures may be classified as focal seizures, generalized seizures, and other seizures. Key players in epileptic therapeutic market include Abbott Laboratories, GlaxoSmithKline plc, Cephalon, Inc., Johnson & Johnson, Pfizer, Inc., Novartis AG, Sunovion Pharmaceuticals, Inc.., Valeant Pharmaceuticals International, Inc., Sanofi S.A. and Shire.
Members associated with Neuropharmacology
- Neurochemistry & Neurotransmission
- Neurotoxicity of Drugs
- Paediatric Neuropharmacology
- Addiction & Psychopharmacology
- Neuronal Stem Cells
- Physiology and Signaling
- Psychiatric Disorders
- Neurological disorders
Top Hospitals in USA
- Mayo Clinic, Rochester, Minnesota
- Johns Hopkins Hospital, Baltimore, Maryland
- Massachusetts General Hospital, Boston
- University of California–San Francisco Medical Center
- Desert Springs Hospital Medical Center, Las Vegas
- University of California–Los Angeles Medical Center
- New York University Langone Medical Center, New York City
- Hospitals of the University of Pennsylvania–Penn Presbyterian
- Northwestern Memorial Hospital, Chicago
Major Neuropharmacology-Neurochemistry related Associations in USA
- American Society for Neurochemistry
- Society for Behavioral Neuroendocrinology
- Society For Neuroscience
- American Psychological Association
- International Parkinson and Movement Disorder Society
- American Neurological Association
- International Society for Neurochemistry (ISN)
- The American Society of Neuroimaging
- American Clinical Neurophysiology Society
- International Neuropsychological Society
- Southern Clinical Neurological Society
- International Parkinson and Movement Disorder Society
Universities in USA
- Stanford University
- University of Nevada
- University of North Carolina—?Chapel Hill
- University of Minnesota
- University of Kentucky
- University of Washington
- University of Texas
- University of California
- University of Maryland
- Trinity University
- Texas Southern University
- University of Houston
The table below denotes 25 neurology products manufactured by different pharmaceutical companies. These products are FDA approved for treating Parkinson's, Alzheimer's, MS, Depression, Schizophrenia, Bipolar Disorder, Insomnia.
The neurology sector has been stuck under a dark cloud of high risk and low approval rates for drugs targeting diseases such as Parkinson's, Alzheimer's and schizophrenia for quite some time. Indeed, we've entered a new era in which pharma is parlaying innovative partnerships and approaches to minimize R&D risk while hedging bets on treatment advances.